Insulet Corporation (PODD) Drops 9.02% on February 05

Equities Staff |

Insulet Corporation (PODD) was one of the Russell 2000's biggest losers for Friday February 05 as the stock slid 9.02% to $28.25, a loss of $-2.8 per share. Starting at an opening price of $30.92 a share, the stock traded between $28.09 and $30.92 over the course of the trading day. Volume was 228,617 shares over 2,414 trades, against an average daily volume of 474,882 shares and a total float of 56.93 million.

The losses send Insulet Corporation down to a market cap of $1.61 billion. In the last year, Insulet Corporation has traded between $40.21 and $24.95, and its 50-day SMA is currently $35.58 and 200-day SMA is $31.54.

Insulet Corp is a medical device company that develops, manufactures and markets OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.

Insulet Corporation is based out of Billerica, MA and has some 519 employees. Its CEO is Patrick J. Sullivan.

For a complete fundamental analysis analysis of Insulet Corporation, check out’s Stock Valuation Analysis report for PODD. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…